World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
121
Citations
75010
World Ranking
3545
National Ranking
96

Overview

Thierry Facon is affiliated with the Centre Hospitalier Régional et Universitaire de Lille in France. Their research primarily focuses on hematology, oncology, and molecular biology, with extensive work on multiple myeloma and related fields.

Their recent publications include studies published in high-impact venues such as The Lancet Oncology and The Lancet. These recent papers are:

  • Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial, 2021, The Lancet Oncology
  • Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†, 2021, Annals of Oncology
  • Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial, 2021, The Lancet
  • Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial, 2020, The Lancet
  • Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial, 2021, The Lancet Oncology

Frequent coauthors in Thierry Facon's collaborative network include:

  • Philippe Moreau
  • Xavier Leleu
  • Aurore Perrot
  • Cyrille Hulin
  • Meletios Α. Dimopoulos

The prominent publication venues where this researcher frequently publishes are:

  • Clinical Lymphoma Myeloma & Leukemia
  • Blood
  • Journal of Clinical Oncology
  • Haematologica
  • Hematology Transfusion and Cell Therapy

Thierry Facon's main fields of study concentrate on Medicine and Biochemistry, Genetics and Molecular Biology, with particular subfields including Hematology, Molecular Biology, Oncology, Genetics, and Organic Chemistry.

The research topics covered extensively involve:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • Peptidase Inhibition and Analysis
  • Cancer Treatment and Pharmacology
  • Chronic Lymphocytic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • HIV/AIDS drug development and treatment

Best Publications

  • A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

    Michel Attal;Jean-Luc Harousseau;Anne-Marie Stoppa;Jean-Jacques Sotto

  • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

    Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin

  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

    Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

    Meletios Dimopoulos;Andrew Spencer;Michael Attal;H. Miles Prince

  • Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

    Michel Attal;Jean-Luc Harousseau;Thierry Facon;François Guilhot

  • Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

    Michel Attal;Valerie Lauwers-Cances;Gerald Marit;Denis Caillot

  • Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.

    Thierry Facon;Jean Yves Mary;Cyrille Hulin;Lotfi Benboubker

  • Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

    Michel Attal;Valerie Lauwers-Cances;Cyrille Hulin;Xavier Leleu

  • Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome

    Hervé Avet-Loiseau;Michel Attal;Philippe Moreau;Catherine Charbonnel

  • Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua

  • Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

    Niccolo Bolli;Hervé Avet-Loiseau;David C. Wedge;Peter Van Loo

  • Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

    Philippe Moreau;Michel Attal;Cyrille Hulin;Bertrand Arnulf

  • Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

    Lotfi Benboubker;Meletios Athanasios Dimopoulos;Angela Dispenzieri;John Catalano

  • Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

    F. Saad;J. E. Brown;C. Van Poznak;T. Ibrahim

  • Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

    Thierry Facon;Shaji Kumar;Torben Plesner;Robert Z Orlowski

  • Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

    Andreas Hochhaus;Hagop M. Kantarjian;Michele Baccarani;Jeffrey H. Lipton

  • Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos

  • Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment

    Catherine Roche-Lestienne;Valerie Soenen-Cornu;Nathalie Grardel-Duflos;Jean-Luc Laı̈

  • Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

    Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca

Frequent Co-Authors

Xavier Leleu
Xavier Leleu Harvard University
Philippe Moreau
Philippe Moreau University of Nantes
Michel Attal
Michel Attal Janssen (Belgium)
Denis Caillot
Denis Caillot Grenoble Alpes University
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Jean-Luc Harousseau
Jean-Luc Harousseau University of Nantes
Paul G. Richardson
Paul G. Richardson Harvard University
Michele Cavo
Michele Cavo University of Bologna
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in expanding your healthcare career options beyond traditional medical school? There are several flexible online degree pathways for aspiring and current healthcare professionals. Many students look for accredited, career-focused programs that offer advanced roles or management opportunities within healthcare.

For those considering healthcare administration, the top cahme accredited mha programs provide a rigorous foundation in leadership and organizational skills needed to excel in hospitals and health systems.

Registered Nurses seeking to advance their education may be drawn to online rn to bsn no clinicals options, which allow for further qualification without traditional clinical on-site requirements—perfect for working nurses.

For practicing nurses aiming to reach the highest levels, there are flexible and accelerated doctoral programs available. Explore dnp online programs as well as options for the shortest dnp program to achieve advanced clinical or leadership roles faster.

Exploring these related online degrees can help you find the right path—whether you’re advancing in nursing or transitioning into healthcare leadership.

Best Scientists Citing Thierry Facon

Trending Scientists

Recently Published Articles